Apricus Biosciences, Inc. (NASDAQ:APRI) Files An 8-K Results of Operations and Financial ConditionItem 2.02.Results of Operations and Financial Condition.
On August2, 2017, Apricus Biosciences, Inc. (the “Company”) issued a press release announcing its results of operations for the six months ended June 30, 2017. The full text of such press release is furnished as Exhibit 99.1 to this report.
In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Item 2.02 of this Current Report on Form 8-K.
Item 2.02.Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No. |
Description |
|
99.1 |
Press Release, dated August 2, 2017 |
***
APRICUS BIOSCIENCES, INC. ExhibitEX-99.1 2 q22017corporateupdateex991.htm EXHIBIT 99.1 Exhibit Exhibit 99.1Apricus Biosciences Provides Corporate Update and Second Quarter 2017 Financial ResultsVitaros Drug-Device Human Factor Studies Successfully CompletedVitaros U.S. NDA Final Draft Completed with Re-Submission Expected in Current QuarterConference Call / Webcast Today,…To view the full exhibit click here
About Apricus Biosciences, Inc. (NASDAQ:APRI)
Apricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT. The Company has over two product candidates in Phase II development, fispemifene for the treatment of symptomatic male secondary hypogonadism and RayVa for the treatment of Raynaud’s phenomenon, secondary to scleroderma. The Company has a commercial product, Vitaros for the treatment of erectile dysfunction (ED), which is in development in the United States, approved in Canada and marketed throughout Europe.
